Imaging and Genetic Biomarkers of Parkinson Disease (PD) Onset and Progression in High-risk Families
|The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.|
|ClinicalTrials.gov Identifier: NCT00273351|
Recruitment Status : Completed
First Posted : January 9, 2006
Last Update Posted : May 9, 2014
|Condition or disease||Intervention/treatment||Phase|
|Parkinson Disease Parkinsonian Syndrome||Drug: [123I]B-CIT||Phase 2|
Individuals who agree to participate in this trial will have a complete screening exam by a neurologist at the Institute for Neurodegenerative Disorders (IND) in New Haven, CT. The exam may include blood tests, urine tests and an electrocardiogram (ECG -tracing of the electrical activity of the heart) to determine eligibility for the trial.
Research subjects will participate in a variety of biomarker assessments including brain imaging, which will take place over a period of two days.
On the first day subjects report to IND after a brief exam subjects will receive a standard dose of Lugol's solution (potassium iodide) by mouth to decrease uptake of the radioactive drug into the thyroid gland. Subjects will be given a standard dose of potassium perchlorate if allergic to iodine.
Next subjects will receive the intravenous (IV - into a vein) injection of the Beta-CIT, a radioactive material that localizes in the brain.
On the second day, about 24 hours after the injection, subjects will return to IND for a SPECT scan. The SPECT camera takes a "picture" of the radiation emitted by the Beta-CIT. This procedure will take approximately 30 minutes.
Subjects will be contacted by phone one week following the injection to monitor adverse (bad or harmful) events possibly related to the imaging procedure.
This two-day imaging procedure, comprehensive neurological testing, and blood collection for genetics and biochemical testing may be repeated every 12 to 18 months during the next five years.
|Study Type :||Interventional (Clinical Trial)|
|Actual Enrollment :||62 participants|
|Intervention Model:||Single Group Assignment|
|Masking:||None (Open Label)|
|Official Title:||Assessment of Pre-symptomatic and Symptomatic Patients With Parkinson Disease to Identify and Characterize Genetic and Phenotypic Biomarkers for Disease Onset and Progression.|
|Study Start Date :||January 2006|
|Actual Primary Completion Date :||January 2008|
|Actual Study Completion Date :||January 2008|
[123I]B-CIT and SPECT imaging
Subjects will receive up to 6 mCi of [123I] B-CIT injected intravenously
- Dopamine transporter density [ Time Frame: 4.5 years ]The dopamine transporter density in individuals at risk for Parkinsonism due to family history compared to healthy controls.
- Correlation of the imaging outcome with both clinical outcomes (olfaction, reaction time, handwriting, etc) and biochemical measures [ Time Frame: 4.5 years ]
To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT00273351
|United States, Connecticut|
|Institute for Neurodegenerative Disorders|
|New Haven, Connecticut, United States, 06510|
|Principal Investigator:||Kenneth L. Marek, MD||President and Senior Scientist|